Independent Director — Audit Committee Financial Expert
United States·Healthcare & Life Sciences·Posted 23 August 2026
Nasdaq-listed mid-cap medical technology company
Actively sourcing
A demand profile the Exchange is actively sourcing against. The sponsor is not confirmed on this board, and we say so rather than implying a signed mandate. Registering interest puts you in front of the sponsor when the brief converts.
The problem this seat exists to solve
The company must disclose whether its audit committee includes an audit committee financial expert under SOX s.407, and the committee must be entirely independent under SEC Rule 10A-3. International expansion has also outrun the board's experience of the markets it now sells into.
The remit
- Serve on a fully independent audit committee and act as the designated financial expert
- Oversee revenue recognition and controls through an international expansion
- Contribute board-level perspective on regulatory pathways outside the United States
- Support the CFO through the reporting demands of a scaling public company
What the sponsor will not compromise on
- Qualification as an audit committee financial expert under SEC rules
- Experience of medical device or diagnostics regulation in more than one jurisdiction
- Independence under Nasdaq Rule 5605 and Exchange Act Rule 10A-3
- Ability to obtain personal EDGAR credentials for Section 16 filings
Terms
- Engagement
- Annual election; typically 6–8 board meetings a year plus committee meetings.
- Compensation
- USD 180,000 – 240,000 in total compensation, substantially in restricted stock.
- Cross-border
- No citizenship or residency test applies. A non-resident should take advice on US tax exposure created by equity compensation before accepting.
- Time commitment in this market
- Typically 5–8 board meetings a year plus committee meetings and continuous between-meeting engagement; audit-committee chairs of listed issuers carry a materially heavier load.
Before you apply — United States
Neither federal securities law, the listing standards nor Delaware corporation law imposes any citizenship or residency test on a director of a US public company.
- Residency test
- None.
- Nationality test
- None.
- Work authorisation
- A foreign national attending board meetings usually travels on a B-1 business visa or under the Visa Waiver Program; board attendance is a recognised permissible business activity. An executive or interim operating role requires work authorisation.
- Tenure limit once appointed
- None, and none is proposed. Long tenure is a live proxy-adviser and institutional-investor issue rather than a rule, and is raised at annual meetings rather than enforced.
Also open in the United States
All mandates in this market →Global ID Exchange
One registration. Every market your record travels to.
Registering against a single brief is fine. Registering once against your whole profile means you are read against every mandate that opens in the markets you can actually be appointed in — statutory, interim and advisory.